A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype

Journal of Medical Virology

Volumn 81, Issue 10, 2009, Pages 1702-1709

  Van Houtte, Margriet ^a   Picchio, Gaston ^b,d   Van Der Borght, Koen ^a   Pattery, Theresa ^a   Lecocq, Pierre ^a   Bacheler, Lee T ^c  

^a Virco BVBA   (Belgium)

^b Virco Lab Inc   (United States)

^c VircoLab Inc   (United States)

^d Tibotec Inc   (United States)

Author keywords

Drug resistance; Drug susceptibility; Genotype; HIV 1; Mutations; Phenotype

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; ASSAY; BIOASSAY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA BASE; DRUG SENSITIVITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN IMMUNODEFICIENCY VIRUS 1; PHENOTYPE; PREDICTION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; GENOTYPE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PHENOTYPE; STATISTICS AS TOPIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69949166547     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21585     Document Type: Article

References (16)

1. Coakley EP, Chappey C, Flandre P, Pesano R, Parkin N, Kohlbrenner V, Hall D, Mayers DL. 2006. Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO's) for tipranavir (TPV), lopinavir (LPV), saquinavir (SQV) and amprenavir (APV) co-administered with ritonavir (r) within the RESIST dataset using the PhenoSense assay (Monogram (MGRM) Biosciences). Antivir Ther 11:S81.
2. Harrigan PR, Montaner JSG, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 15:1671-1677. (Pubitemid 32918121)
3. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269-276. (Pubitemid 28114430)
4. Parkin NT, Helmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. 2004. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:437-443. (Pubitemid 38141699)
5. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920-928. (Pubitemid 30165271)
6. Qari SH, Respess H, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W. 2002. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 40:31-35. (Pubitemid 34027597)
7. Ross L, Boulmé R, Fisher R, Hernandez J, Florance A, Schmit JC, Williams V. 2005. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the Antivirogram and Phenosense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses 21:933-939. (Pubitemid 41785779)
8. Snedecor GW, Cochran WG. 1967. Statistical methods. 6th edition. Ames, Iowa, USA:The Iowa State University Press, p. 750.
9. Verlinden Y, Vermeiren H, Lecocq P, Bacheler L, McKenna P, Vanpachtenbeke M, Laenen-Horvat LI, Van Houtte M, Stuyver LJ. 2005. Assessment of the Antivirogram performance over time including a revised definition of biological test cut-off values. Antivir Ther 10:S51.
10. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P, The Virco Clinical Response Collaborative Team. 2007. Prediction of HIV-1 drug susceptibility phenotype from viral genotype using linear regression modeling. J Virol Methods 145:47-55.
11. Wang K, Samudrala R, Mittler J. 2004a. Weak agreement between Antivirogram and PhenoSense assays in predicting reduced susceptibility to antiretroviral drugs. J Clin Microbiol 42:2353-2354. (Pubitemid 38637886)
12. Wang K, Samudrala R, Mittler JE. 2004b. Antivirogram or PhenoSense: A comparison of their reproducibility and an analysis of their correlation. Antivir Ther 9:703-712. (Pubitemid 39434333)
13. Winters B, Rinehart A, Montaner J, Harrigan P, Castor D, Hammer S, Wasikowski B, Miller M, Emery S, van Leth F, Robinson P, Baxter J, Gazzard B, Pozniak A, Bacheler L. 2005. Validation of clinically relevant breakpoints for HIV-1 phenotypic resistance data. 12th Conf Retroviruses Opportun Infect, Boston, MA, abstract 705.
14. Winters B, Montaner J, Harrigan R, Pellegrin I, Tisdale M, Seekins D, Butcher D, Villacian J, Van Craenenbroeck E, Bacheler L. 2007. Development of VircoTYPE HIV-1 resistance analysis including clinical cutoffs for ritonavir-boosted atazanavir and fosamprenavir. 14th Conf Retroviruses Opportun Infect, Los Angeles, CA, abstract 611.
15. Winters B, Montaner J, Harrigan R, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, Perez-Elias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van Craenenbroeck E, Bacheler L. 2008. Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 48:26-34. (Pubitemid 351600859)
16. Zhang J, Rhee SH, Taylor J, Shafer R. 2005. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 38:439-444. (Pubitemid 40381554)